Home/Filings/4/0001127602-25-013778
4//SEC Filing

Bradner James E. 4

Accession 0001127602-25-013778

CIK 0000318154other

Filed

May 7, 8:00 PM ET

Accepted

May 8, 8:49 PM ET

Size

7.6 KB

Accession

0001127602-25-013778

Insider Transaction Report

Form 4
Period: 2025-05-06
Bradner James E.
EVP, R&D, & Chief Sci. Officer
Transactions
  • Award

    Common Stock

    2025-05-06+3,54929,753 total
  • Award

    Nqso (Right to Buy)

    2025-05-06$270.44/sh+22,944$6,204,97522,944 total
    Exercise: $270.44From: 2026-05-06Exp: 2035-05-06Common Stock (22,944 underlying)
Footnotes (3)
  • [F1]The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/6/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
  • [F2]These shares include 948 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
  • [F3]These non-qualified stock options were granted pursuant to the Equity Incentive Plan and are exercisable in four equal annual installments of 25% each commencing on 5/6/2026.

Issuer

AMGEN INC

CIK 0000318154

Entity typeother

Related Parties

1
  • filerCIK 0002005159

Filing Metadata

Form type
4
Filed
May 7, 8:00 PM ET
Accepted
May 8, 8:49 PM ET
Size
7.6 KB